OTCQB:PTLF



Thank you for visiting the PetLife Pharmaceuticals, Inc. Investor Relations and Information page. We are currently updating our website and will provide a secure access section for investors and the public sections for information and data. Any questions, please CLICK HERE

1 844 4 PETLIFE
(844) 473-8543
info@petlifelifepharma.com

PetLife Pharmaceuticals Updates Shareholders on the Company Progress with Vitalzul™ Studies and Additional Product Offerings

Hancock, MD, Dec. 01, 2016 (GLOBE NEWSWIRE)

Dear Fellow Shareholder,

Your company continues to make progress with the development and testing of our flagship product Vitalzul™. The PetLife team has recently presented at Investor conferences in San Francisco, Toronto, Dallas, Las Vegas and Boston and has plans to present our company next month in Los Angeles. Additionally, we will be presenting to investors during the JP Morgan conferences in early 2017.

We continue with our pre-INAD studies and are pleased that we will have our dosing and preliminary toxicology studies of Vitalzul™ completed by mid to late December. Armed with those studies we then plan to discuss our Clinical and Regulatory program with the FDA/CVM. We are also building out our portfolio of product offerings and will soon announce several new natural based veterinary products.

We continue to monitor the world literature and have noted a recent manuscript from Saudi Arabia outlining the positive effects of scorpion venom on a number of cancer cell lines. This supports our current efforts in partnership with InnoVision.

The market has recently been a bit harsh with our stock. Low trading volume can often result in extreme volatility and we certain have seen this recently. This volatility does not affect the core mission of the company but certainly is concerning to management. We are making efforts to support our stock price by continuing our pre-INAD studies on an aggressive schedule and by presenting our message through social media and investor presentations.

Our mission at PetLife Pharmaceuticals is critically important to the health of our companion animals. I ask that you continue to support the company and help spread the message. Additionally, with the pull back in stock price, it is an excellent time to show your support by purchasing additional stock (OTCQB: PTLF) for your portfolio.

If you haven’t visited our website (www.petlifepharma.com) or our Facebook page (https://facebook.com/PetLifePharmaceticals ) recently please take a minute to do so today and invite your friends and acquaintances to support our mission.

Ralph T Salvagno M.D.
CEO PetLife Pharmaceuticals Inc.

PetLife’s 506 Private Placement Memorandum is available only to accredited investors.

LEGAL COUNSEL
Lance Brunson, Esq., of Brunson Chandler & Jones PLLC (“BCJ”)
175 S. Main Street, Suite 1410, Salt Lake City, Utah 84111

Independent Accountant
LBB & Associates Ltd., LLP
10260 Westheimer Road, Suite 310, Houston, Texas 77042

Transfer Agent
Empire Stock Transfer

Auditors
Carlos Lopez, LBB & Associates Houston Texas

  IR/PR Firm
Gregory FCA


Press Release Information

April 18, 2017
PetLife Finalizes Negotiations for Dr. Geoff’s Real Food for Pets
HANCOCK, Md.--(BUSINESS WIRE)--
PetLife Pharmaceuticals, Inc. (PTLF) (the “Company”), a developer of a new generation of high-potency veterinary cancer medications and nutraceuticals for pets, announced today that it has finalized the negotiations for the acquisition of Dr. Geoff’s Real Food for Pets™. The closing of the acquisition of the trademarked brands and the natural pet food product line is projected to occur within two weeks. VIEW PR

April 12, 2017
PetLife: Holistic Pet Health is Next Big Trend in Veterinary Medicine
Business Wire
HANCOCK, Md.--(BUSINESS WIRE)--
PetLife Pharmaceuticals, Inc. (PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, released today an overview of the current state of holistic pet health practices in veterinary medicine. VIEW RELEASE

March 21, 2017
PetLife Supersedes Expectations for the Acquisition of Dr. Geoff’s Real Food for Pets
March 21, 2017 07:00 AM Eastern Daylight Time
HANCOCK, Md.--(BUSINESS WIRE)--PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it has proceeded to the next expected stage of acquiring Dr. Geoff’s Real Food for Pets™ and simultaneously has expanded plans for a national rollout.
VIEW PRESS RELEASE

March 7, 2017
PetLife Pharmaceuticals Provides an Eye-Opening View on a Recession Resistive Industry - HANCOCK, Md.--(BUSINESS WIRE)--PetLife Pharmaceuticals, Inc. (PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, released today an overview of the $63 billion companion pet healthcare industry. Empty nesters, reduced fertility, and pet owners prioritizing pet care over their own expenses all contribute to the resiliency of the pet care industry. PetLife’s continuous development of multiple product lines aims to serve the growing companion pet healthcare market, bolstering its market reach and thereby solidifying the company both on a revenue/financial point of view as a natural, solution-focused company.
VIEW PRESS RELEASE

February 28, 2017
PetLife Pharmaceuticals Signs Letter of Intent to Acquire Healthy Life Pets Brand - HANCOCK, Md.--(BUSINESS WIRE)--PetLife Pharmaceuticals, Inc. (PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it signed a Letter of Intent to acquire the assets of Healthy Life Pets. Most commonly known as Dr. Geoff’s Real Food for Pets™, assets in this brand include six SKUs of retail-ready products, including both canned food and antioxidant supplements.
VIEW PRESS RELEASES

February 20, 2017

PetLife Pharmaceutical Taps National Public Relations Firm to Help Bring to Market Cancer Treatment Originally Developed by Cuba- HANCOCK, Md.--(BUSINESS WIRE)--PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, announced today that it has retained Gregory FCA Communications, Inc., one of the nation’s largest public relations agencies, to help bring to market a breakthrough cancer treatment for pets produced from the venom of the blue scorpion.
VIEW PRESS RELEASES

February 10, 2017
World Renowned Veterinary Nutritionist Dr. R. Geoffrey Broderick Continues Groundbreaking Efforts to Help Animals by Joining PetLife Pharmaceuticals, Inc. as the Chairman of Product Development and Advisory Board - Hancock, MD, Feb. 09, 2017 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and nutraceuticals for pets, augments the advisory board and prepares for new and expanded product lines with the appointment of Dr. R. Geoffrey Broderick as Chairman of Product Development. Dr. Broderick, one of the world’s most famous veterinarians, comes to PetLife with an intricate knowledge of the pet industry.
VIEW PRESS RELEASES

January 10, 2017
PetLife Pharmaceuticals reports the First of Three Preclinical Studies in their pre-INAD Process for Vitalzul. Blue Scorpion Venom Toxicity Study Results Show No Adverse Reactions across Multiple Dosing Levels.
VIEW PRESS RELEASES

December 7, 2016
PetLife Pharmaceuticals Enters Negotiations with Key Founders of InnoVision Therapeutics to Discuss Expansion of its Core Product Line
VIEW PRESS RELEASES

December 6, 2016
PetLife Pharmaceuticals’ CEO Dr. Salvagno Provides White Paper on “Venenotherapy” While Preparing for FDA Submission
VIEW PRESS RELEASES

December 1, 2016
PetLife Pharmaceuticals Updates Shareholders on the Company Progress with Vitalzul™ Studies and Additional Product Offerings
VIEW PRESS RELEASES

November 15, 2016
PetLife Pharmaceuticals Notes Recent Cuban Research Providing Profound Evidence of Caribbean Blue Scorpion Venom's Ability to Eradicate Cancer Cells as Continued Support for PetLife's pre- INAD Studies of Vitalzul™
VIEW PRESS RELEASES

October 27, 2016
PetLife Pharmaceuticals and Lumleian, LLC Announce Partnership to Advance Development and Commercialization of Promising Veterinary Health Pipeline
VIEW PRESS RELEASES

October 24, 2016
PetLife Pharmaceuticals Announces the Addition of a Seasoned Marketing Specialist and Investor, Mrs. Vyvyan Campbell, to the Board of Directors
VIEW PRESS RELEASES

October 19, 2016
PetLife Pharmaceuticals Announces the Addition of Dr. Simon Wood PhD as the Company’s new Scientific Officer with plans to expand its Current Portfolio of Veterinarian Drugs and Nutraceuticals
VIEW PRESS RELEASES

SEC FILINGS

NOTE: IF YOU HAVE PROBLEMS OPENING FILES PLEASE VISIT

SEC.GOV PETLIFE UPDATED INFORMATION - CLICK HERE



Filings Format Description Filing Date File/Film Number
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-17-003868 (34 Act)  Size: 3 MB
2017-04-14 000-52445
17762868
SC 13D  Documents General statement of acquisition of beneficial ownership
Acc-no: 0001477932-17-001629 (34 Act)  Size: 612 KB
2017-04-07 005-82533
17750104
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001493152-17-002852 Size: 14 KB
2017-03-27
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001493152-17-002849 Size: 13 KB
2017-03-24
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001493152-17-002847 Size: 3 KB
2017-03-24
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-17-001329 (34 Act)  Size: 1 MB
2017-02-10 000-52445
17593133
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-17-001329 (34 Act)  Size: 1 MB
2017-02-10 000-52445
17593133
8-K  Documents Current report, item 5.02
Acc-no: 0001493152-17-001078 (34 Act)  Size: 26 KB
2017-02-03 000-52445
17570896
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB
Acc-no: 0001493152-17-000431 (34 Act)  Size: 31 KB
2017-01-13 000-52445
17526460
10-K  Documents   Interactive Data Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001493152-16-016114 (34 Act)  Size: 2 MB
2016-12-21 000-52445
162064643
NT 10-K  Documents Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Acc-no: 0001493152-16-015634 (34 Act)  Size: 30 KB
2016-12-05 000-52445
162032602
8-K  Documents Current report, item 5.02
Acc-no: 0001493152-16-014213 (34 Act)  Size: 27 KB
2016-10-24 000-52445
161947776
8-K  Documents Current report, item 1.01
Acc-no: 0001493152-16-013223 (34 Act)  Size: 22 KB
2016-09-09 000-52445
161878940
8-K  Documents Current report, item 1.01
Acc-no: 0001493152-16-013094 (34 Act)  Size: 17 KB
2016-09-02 000-52445
161868796
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-16-011672 (34 Act)  Size: 784 KB
2016-07-21 000-52445
161777259
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB
Acc-no: 0001493152-16-011563 (34 Act)  Size: 28 KB
2016-07-15 000-52445
161768982
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001074140-16-000002 Size: 3 KB
2016-06-22
D  Documents Notice of Exempt Offering of Securities, item 06c
Acc-no: 0001074140-16-000001 (33 Act)  Size: 6 KB
2016-06-22 021-265521
161725318
DEF 14C  Documents Other definitive information statements
Acc-no: 0001493152-16-010126 (34 Act)  Size: 56 KB
2016-05-20 000-52445
161664875
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-16-009048 (34 Act)  Size: 801 KB
2016-04-19 000-52445
161579733
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB
Acc-no: 0001493152-16-008956 (34 Act)  Size: 28 KB
2016-04-15 000-52445
161574074
UPLOAD  Documents [Cover]SEC-generated letter
Acc-no: 0000000000-16-070262 Size: 36 KB
2016-03-30
10-K/A  Documents [Amend] Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001493152-16-008263 (34 Act)  Size: 62 KB
2016-03-25 000-52445
161528314
8-K  Documents Current report, item 5.02
Acc-no: 0001493152-16-008259 (34 Act)  Size: 17 KB
2016-03-25 000-52445
161528227
CORRESP  Documents [Cover]Correspondence
Acc-no: 0001493152-16-008261 Size: 89 KB
2016-03-24
UPLOAD  Documents [Cover]SEC-generated letter
Acc-no: 0000000000-16-068777 Size: 163 KB
2016-03-17
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-16-006776 (34 Act)  Size: 937 KB
2016-01-14 000-52445
161342454
10-K/A  Documents [Amend] Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001493152-16-006692 (34 Act)  Size: 30 KB
2016-01-08 000-52445
161332575
10-K/A  Documents   Interactive Data [Amend] Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001493152-16-006631 (34 Act)  Size: 1 MB
2016-01-06 000-52445
161325304
10-K  Documents   Interactive Data Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001493152-16-006570 (34 Act)  Size: 1 MB
2016-01-05 000-52445
161319989
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-15-006520 (34 Act)  Size: 974 KB
2015-12-31 000-52445
151316233
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-15-006514 (34 Act)  Size: 947 KB
2015-12-31 000-52445
151316196
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001493152-15-006511 (34 Act)  Size: 975 KB
2015-12-31 000-52445
151316170
10-K/A  Documents   Interactive Data [Amend] Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001493152-15-006481 (34 Act)  Size: 1 MB
2015-12-31 000-52445
151315440
8-K  Documents Current report, items 4.01 and 9.01
Acc-no: 0001493152-15-006412 (34 Act)  Size: 36 KB
2015-12-28 000-52445
151307906
NTN 10K  Documents Notices of Late Filings of Form 10-K or 10-KSB
Acc-no: 0001493152-15-005993 (34 Act)  Size: 30 KB
2015-12-02 000-52445
151263457
SC 13D  Documents General statement of acquisition of beneficial ownership
Acc-no: 0001360865-15-000011 (34 Act)  Size: 30 KB
2015-05-15 005-82533
15871144
NT 10-Q  Documents Notification of inability to timely file Form 10-Q or 10-QSB
Acc-no: 0001360865-15-000001 (34 Act)  Size: 12 KB
2015-01-15 000-52445
15529432
10-K  Documents Annual report [Section 13 and 15(d), not S-K Item 405]
Acc-no: 0001360865-14-000061 (34 Act)  Size: 442 KB
2014-12-16 000-52445
141288078
NT 10-K  Documents Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405
Acc-no: 0001360865-14-000059 (34 Act)  Size: 12 KB
2014-12-01 000-52445
141257550
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001360865-14-000053 Size: 3 KB
2014-10-03
8-K  Documents Current report, item 5.02
Acc-no: 0001360865-14-000052 (34 Act)  Size: 10 KB
2014-10-03 000-52445
141138909
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001360865-14-000051 Size: 3 KB
2014-09-29
SC 13D  Documents General statement of acquisition of beneficial ownership
Acc-no: 0001360865-14-000050 (34 Act)  Size: 17 KB
2014-09-29 005-82533
141125941
SC 13D  Documents General statement of acquisition of beneficial ownership
Acc-no: 0001360865-14-000049 (34 Act)  Size: 25 KB
2014-09-29 005-82533
141125929
SC 13D  Documents General statement of acquisition of beneficial ownership
Acc-no: 0001360865-14-000048 (34 Act)  Size: 17 KB
2014-09-29 005-82533
141125913